PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
100.00%
Net income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 4.39%. Joel Greenblatt would see it as a clear outperformance relative to peers.
-100.00%
D&A shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.18%. Seth Klarman would see a short-term earnings benefit if capacity is sufficient.
200.26%
Deferred tax growth of 200.26% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would see a difference that might matter for future cash flow if significant.
-100.00%
SBC declines yoy while Drug Manufacturers - Specialty & Generic median is -6.36%. Seth Klarman would see a near-term advantage in less dilution unless new hires are needed.
100.00%
Under 50% of Drug Manufacturers - Specialty & Generic median of 73.71% or exceeding it in the negative sense. Jim Chanos would suspect a bigger working capital drain if growth is not justified by sales.
100.00%
AR growth of 100.00% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or more relaxed credit if revenue is not matching it.
100.00%
Inventory growth of 100.00% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question if expansions or new product lines require extra stock.
100.00%
AP growth of 100.00% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or credit policies affecting the difference.
-16.67%
Other WC usage shrinks yoy while Drug Manufacturers - Specialty & Generic median is -15.11%. Seth Klarman would see an advantage if top-line is stable or growing.
-1295.23%
Other non-cash items dropping yoy while Drug Manufacturers - Specialty & Generic median is -116.72%. Seth Klarman would see a short-term advantage if real fundamentals remain intact.
-15.34%
Negative CFO growth while Drug Manufacturers - Specialty & Generic median is -15.74%. Seth Klarman would suspect a firm-specific operational weakness if peers maintain growth.
100.00%
CapEx growth under 50% of Drug Manufacturers - Specialty & Generic median of 5.92% or substantially above. Jim Chanos would see potential overspending or misallocation if top-line is not keeping pace.
-100.00%
Acquisition spending declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would note reduced M&A risk if growth continues organically.
100.00%
Purchases growth of 100.00% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or new strategic positions driving the difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
78.29%
Under 50% of Drug Manufacturers - Specialty & Generic median of 10.84% if negative or well above if positive. Jim Chanos sees potential overspending or major liquidity drain overshadowing typical sector levels.
-16.32%
Debt repayment yoy declines while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman fears increased leverage if expansions do not yield quick returns.
-32.23%
We reduce issuance yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see an advantage in preserving per-share value unless expansions are neglected.
No Data
No Data available this quarter, please select a different quarter.